文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

汉方药六君子汤治疗化疗所致厌食的疗效(RICH试验):一项随机对照试验的研究方案

The efficacy of the Kampo medicine rikkunshito for chemotherapy-induced anorexia (RICH trial): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-10-18

RICH试验为安慰剂对照、双盲、随机对照试验,旨在确定汉方药六君子汤(TJ-43)预防肺癌患者含顺铂化疗所致厌食的疗效。计划招募60例拟接受含顺铂化疗的肺癌患者,随机分配至TJ-43组(A组)或安慰剂组(B组),每臂30例,主要终点为从第0天至含顺铂化疗第7天膳食摄入量的变化。

要点

  • RICH试验采用安慰剂对照、双盲、随机设计,评估六君子汤(TJ-43)预防含顺铂化疗所致厌食的疗效。
  • 计划纳入60例拟接受含顺铂化疗的肺癌患者,随机分配至TJ-43组(A组)或安慰剂组(B组),每臂30例。
  • 主要终点为从第0天(化疗开始前一天)至含顺铂化疗第7天膳食摄入量的变化。

核心结论

  • 该试验旨在检验六君子汤(TJ-43)减轻肺癌患者含顺铂化疗所致厌食并维持食物摄入的疗效。

研究设计与样本

  • 安慰剂对照、双盲、随机对照试验。
  • 计划招募60例拟接受含顺铂化疗的肺癌患者,随机分配至TJ-43组(A组)或安慰剂组(B组),每臂30例。
  • 患者接受一个化疗周期(连续21或28天)的TJ-43或安慰剂治疗,研究者和患者全程对治疗分配设盲。
  • 自2014年11月起招募,计划于2017年10月完成招募。

关键数值与推荐

  • 主要终点为从第0天(化疗开始前一天)至含顺铂化疗第7天膳食摄入量的变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cisplatin is a key drug in lung cancer therapy. However, cisplatin is also well known to induce gastrointestinal disorders, such as chemotherapy-induced nausea and vomiting, anorexia, and weight loss. These symptoms sometimes affect patients' quality of life and make continuation of chemotherapy difficult. Anorexia is a cause of concern for patients with cancer because a persistent loss of appetite progresses to cancer cachexia. Although evidence-based management for chemotherapy has recently been established, there is room for improvement. METHODS/DESIGN: This placebo-controlled, double-blind, randomized trial will aim to determine the efficacy of the traditional Japanese Kampo medicine rikkunshito (TJ-43) for preventing anorexia caused by cisplatin-including chemotherapy in patients with lung cancer. Patients with lung cancer who plan to receive cisplatin-including chemotherapy will be recruited. Patients who provide written consent will be randomly allocated to receive either TJ-43 (arm A) or placebo (arm B) for one course of chemotherapy (21 or 28 consecutive days). Investigators and patients will be masked to the treatment assignment throughout the trial. The primary endpoint will be evaluated as the change in dietary intake from day 0 (the day before the start of chemotherapy) to day 7 of cisplatin-including chemotherapy. The two arms of the trial will comprise 30 patients each. From November 2014, a total of 60 patients will be recruited, and recruitment for the study is planned to be complete by October 2017. DISCUSSION: This trial is designed to examine the efficacy of rikkunshito (TJ-43) for reducing anorexia and maintaining food intake caused by cisplatin-including chemotherapy in patients with lung cancer. TRIAL REGISTRATION: Japan Pharmaceutical Information Center Clinical Trials Information (JAPIC CTI), trial registration: JAPIC CTI-142747 . Registered on 15 December 2014; the RICH trial.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Inoue T, Takagi H, Owada Y, et al. The efficacy of the Kampo medicine rikkunshito for chemotherapy-induced anorexia (RICH trial): study protocol for a randomized controlled trial. Trials. 2017. PMID: 29047408. doi:10.1186/s13063-017-2227-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。